Semaglutide & Tirzepatide Side Effects: Complete Guide to Contraindications
This article has been recently updated with the latest information and guidelines.
Medically Reviewed
Trimi Medical Review Team
Clinical review workflow for GLP-1 safety, dosing, and access content
Team-based medical review process documented in Trimi's Medical Review Policy
Last reviewed: January 25, 2026
What are the common side effects and contraindications for semaglutide and tirzepatide?
Common side effects include nausea (20-44%), diarrhea, constipation, and decreased appetite—most resolve within 4-8 weeks. Contraindications include personal/family history of medullary thyroid carcinoma, MEN2 syndrome, pregnancy, and hypersensitivity to the medication.
Medically Reviewed
Dr. Sarah Mitchell
Board-Certified Obesity Medicine Specialist
Last reviewed: January 25, 2026
Understanding the side effect profile and contraindications of semaglutide and tirzepatide is essential for safe, effective weight loss treatment. This comprehensive guide covers everything from common GI symptoms to serious warnings, helping you make informed decisions with your healthcare provider.
Medical Disclaimer
This information is for educational purposes only. Always consult with a qualified healthcare provider before starting, stopping, or modifying any medication. Individual responses vary, and your provider can assess your specific risk factors.
Common Side Effects Overview
Both semaglutide and tirzepatide belong to the GLP-1 receptor agonist class, sharing similar side effect profiles. The majority of side effects are gastrointestinal in nature and tend to diminish as your body adapts to the medication.
Semaglutide (Ozempic®/Wegovy®)
- Nausea: 34% of patients
- Diarrhea: 30% of patients
- Vomiting: 11% of patients
- Constipation: 24% of patients
- Abdominal pain: 20% of patients
Tirzepatide (Mounjaro®/Zepbound®)
- Nausea: 44% of patients
- Diarrhea: 31% of patients
- Vomiting: 18% of patients
- Constipation: 23% of patients
- Decreased appetite: 25% of patients
Side Effect Timeline: What to Expect Week by Week
One of the most common questions patients ask is how long side effects will last. Based on clinical trial data and real-world patient experience, here is a typical timeline for GI side effects during semaglutide and tirzepatide treatment. Understanding this progression helps set realistic expectations and keeps patients motivated through the initial adjustment period.
Week 1-2: Peak GI Symptoms
This is when side effects are most noticeable. Nausea typically peaks within the first few days after each injection, and reduced appetite is common. Many patients experience mild to moderate nausea, occasional diarrhea or constipation, and a significant decrease in hunger signals. These symptoms are a sign that the medication is working on your GLP-1 receptors.
Week 3-4: Symptoms Begin Improving
The majority of patients notice a meaningful improvement by the end of week three. Your body is adapting to the medication, and GI symptoms become less frequent and less intense. Nausea episodes become shorter and milder, appetite begins to normalize (though still reduced), and energy levels often start to improve as your body adjusts.
Week 5-8: Significant Improvement
By this stage, most side effects have become minimal or completely resolved. Clinical data shows that over 75% of patients report little to no GI discomfort by week eight. The weight loss benefits become more apparent during this phase, and patients typically feel well-adjusted to their current dose. This is also when providers may consider the first dose increase if clinically appropriate.
Month 3+: Steady State
It is rare to experience ongoing GI issues after three months of consistent treatment. At this point, patients have typically adapted fully to their maintenance dose. Any residual effects are usually very mild and manageable. Patients in the STEP and SURMOUNT trials who continued therapy past 12 weeks reported minimal ongoing GI complaints, with satisfaction rates exceeding 90%.
Absolute Contraindications
Certain conditions make semaglutide and tirzepatide unsafe. These absolute contraindications require choosing alternative treatments:
Do Not Use If You Have:
- Personal or family history of medullary thyroid carcinoma (MTC)
GLP-1 medications carry a black box warning due to thyroid C-cell tumors observed in animal studies. Learn more about the semaglutide thyroid cancer risk and what it means for patients.
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
This genetic condition increases thyroid cancer risk
- Known hypersensitivity to semaglutide or tirzepatide
Previous allergic reactions to the medication or its components
- Pregnancy or breastfeeding
Discontinue at least 2 months before planned conception. Read our guides on semaglutide and pregnancy and semaglutide fertility considerations for women over 35.
Use With Caution
These conditions don't necessarily prevent use but require careful monitoring and discussion with your healthcare provider:
History of pancreatitis
Increased risk of recurrence; monitor for symptoms
Severe gastrointestinal disease
Gastroparesis, inflammatory bowel disease may worsen
Diabetic retinopathy
Rapid glucose improvement may temporarily worsen
Kidney impairment
Start at lower doses; monitor hydration
Concurrent insulin or sulfonylureas
Dose adjustment needed to prevent hypoglycemia
Gallbladder disease
Rapid weight loss increases gallstone risk. Learn about GLP-1 gallbladder issues and prevention.
Serious But Rare Complications
While uncommon, these serious side effects require immediate medical attention. Clinical trial data shows these occur in less than 1% of patients:
Acute Pancreatitis (0.3%)
Inflammation of the pancreas requiring immediate care. Symptoms include severe upper abdominal pain radiating to the back, nausea, and vomiting that doesn't improve.
⚠️ Seek emergency care for persistent severe abdominal pain
Gallbladder Problems (0.5-2%)
Rapid weight loss can increase gallstone formation. Symptoms include right-sided upper abdominal pain, especially after eating fatty foods, and potential fever. See our detailed guide on GLP-1 gallbladder issues and prevention strategies.
⚠️ Report persistent right-sided abdominal pain to your provider
Severe Allergic Reactions (<0.1%)
Rare anaphylactic reactions can occur. Signs include difficulty breathing, severe rash, swelling of face/throat, rapid heartbeat, and dizziness.
⚠️ Call 911 immediately for signs of anaphylaxis
Managing Side Effects Successfully
The good news: most side effects are manageable with proper strategies. For a deeper dive, read our complete guide to managing GI side effects on semaglutide. Here's how Trimi's approach helps patients succeed:
Evidence-Based Side Effect Management
Gradual increases every 4 weeks allow your body to adapt
Smaller, frequent meals and avoiding fatty/spicy foods reduce GI symptoms by 40%. Explore our best foods and recipes for semaglutide and semaglutide diet plan for meal ideas.
Drinking 64+ oz water daily prevents dehydration and reduces nausea
Taking medication before bed can minimize daytime nausea
24/7 messaging with Trimi providers for concerns and adjustments
Semaglutide vs Tirzepatide: Side Effect Comparison
While both medications share similar GI side effect profiles, there are meaningful differences in tolerability, discontinuation rates, and how quickly side effects resolve. Understanding these differences can help you and your provider choose the right medication for your needs. For a broader look at all available options, see our guide to comparing popular GLP-1 drugs.
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Overall nausea rate | ~34% of patients | ~44% of patients |
| Vomiting rate | ~11% of patients | ~18% of patients |
| Discontinuation due to GI side effects | 4.5% (STEP trials) | 6.6% (SURMOUNT trials) |
| Median time to GI symptom resolution | 4-6 weeks | 5-8 weeks |
| Injection site reactions | 3.2% | 5.6% |
| Hypoglycemia risk (non-diabetic) | Very low (<1%) | Very low (<1%) |
| Average weight loss at 72 weeks | ~15-17% body weight | ~20-22% body weight |
While tirzepatide shows slightly higher initial GI side effect rates, its dual GIP/GLP-1 mechanism often delivers greater weight loss results. For patients who are sensitive to nausea or have a history of GI issues, semaglutide may be the gentler starting point. Patients who tolerate the initial adjustment period well on either medication tend to have comparable long-term tolerability. Your Trimi provider will help determine which medication best fits your health profile and goals.
Drug Interactions
GLP-1 receptor agonists can interact with other medications in important ways. Because these drugs slow gastric emptying, they may affect the absorption and timing of oral medications. Always provide your healthcare provider with a complete list of all medications, supplements, and over-the-counter drugs you take. For comprehensive guidance, review our resources on semaglutide drug interactions, tirzepatide medication interactions, and safe GLP-1 use with other medications.
Insulin & Sulfonylureas
Combining GLP-1 medications with insulin or sulfonylureas (such as glipizide, glyburide, or glimepiride) significantly increases the risk of hypoglycemia. Blood sugar can drop to dangerously low levels. Providers typically reduce insulin doses by 20-50% when starting a GLP-1 agonist and closely monitor glucose levels during the titration period. Sulfonylurea doses may also need reduction. Never adjust diabetes medication doses on your own.
Oral Contraceptives
Because GLP-1 agonists slow gastric emptying, they can delay the absorption of oral contraceptive pills. This delayed absorption may reduce the effectiveness of birth control during the initial weeks of GLP-1 therapy and after dose increases. Patients are advised to use a backup contraceptive method (such as condoms) for 4 weeks after starting or increasing their GLP-1 dose. Alternatively, non-oral contraceptives (IUDs, implants, patches) are not affected.
Thyroid Medications (Levothyroxine)
Patients taking levothyroxine for hypothyroidism should be aware that delayed gastric emptying can alter absorption of this medication. Thyroid hormone levels (TSH) should be monitored more frequently when initiating GLP-1 therapy. Your provider may recommend taking levothyroxine at least 30-60 minutes before or after meals and adjusting timing relative to your GLP-1 injection day. Dose adjustments may be needed based on lab results.
Blood Thinners (Warfarin)
While no direct pharmacological interaction has been identified between GLP-1 agonists and warfarin, the changes in diet and food intake that accompany GLP-1 therapy can alter vitamin K intake, which directly affects warfarin's effectiveness. Patients on warfarin should have their INR (International Normalized Ratio) monitored more frequently during the first several weeks of GLP-1 treatment and after any significant dietary changes. Dose adjustments to warfarin may be necessary.
General Absorption Considerations
Any oral medication with a narrow therapeutic window (meaning small differences in blood levels can affect safety or efficacy) deserves extra attention. This includes medications like certain antibiotics, antiepileptics, and immunosuppressants. Discuss all of your medications with your provider before starting GLP-1 therapy. In many cases, simply monitoring levels or adjusting timing is sufficient to ensure safe concurrent use.
Trimi's Safety-First Approach
At Trimi, patient safety is our top priority. Our board-certified physicians thoroughly evaluate each patient before prescribing, ensuring you're an appropriate candidate for GLP-1 therapy. The process begins with our comprehensive signup and medical assessment, and continues with ongoing support through the Trimi patient portal for refills and dose changes.
Patients continue treatment successfully
Provider access for concerns
Discontinuation due to side effects
Ready to Start Safely?
Get a comprehensive medical evaluation with a board-certified physician who will assess your candidacy and create a personalized treatment plan.
Start Your Free Consultation"The key to successful GLP-1 therapy is proper patient selection, gradual dose titration, and proactive side effect management. With these elements in place, the vast majority of patients can tolerate these medications well while achieving clinically meaningful weight loss."
Clinical Safety Research
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).
Ready to Start Your Weight Loss Journey?
Get started with physician-guided GLP-1 treatment from the comfort of your home.
Get Started TodayWritten by Dr. Sarah Mitchell
MD, ABOM - Board-Certified Obesity Medicine Specialist
Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.
Editorial Standards
Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.
Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.